Global Malaria Vaccines Market Is Estimated To Witness High Growth Owing To Increasing Prevalence Of Malaria In Low-Income Nations And Rising Investment For Healthcare Infrastructure

Malaria Vaccines Market

Overview:

Malaria is a devastating disease that kills millions of children in sub-Saharan Africa each year. A new vaccine may save them, and many others. The World Health Organization has endorsed the first malaria vaccine, RTS,S/AS01, also known as Mosquirix, after years of testing. The vaccine targets Plasmodium falciparum, the most common and lethal of four parasite species that cause malaria.

Increased funding from governmental and non-governmental organisations is anticipated to provide players in the global Preventive Vaccines Market with lucrative growth opportunities.

RTS,S is a protein-based vaccine that delivers a small part of the malaria parasite antigen, sporozoites. The vaccine is designed to stimulate the immune system to respond to this stage of the parasite's life cycle. An ideal malaria vaccine would attempt to target more than one stage of the parasite's development. It might include a protein that blocks the parasite's ability to enter red blood cells, or an antibody that can block the formation of the merozoites from the parasite’s surface proteins.

Market Dynamics:

Rising agreements are estimated to augment growth of the global Malaria Vaccines Market over the forecast period. For instance, GlaxoSmithKline plc and Bharat Biotech International signed an agreement in January 2021, for getting technology from GSK for supplying the world’s first vaccine against malaria. Moreover, rising cost of drug development are anticipated to restrain growth of the global malaria vaccines for market over the forecast period.

Impact of COVID-19:

COVID-19 outbreak was first reported in China in 2019 and in 2020 it was declared as a public health emergency by the World Health Organization. The pandemic led to shutting down of many businesses across the world. The pandemic also had a long-term impact on several businesses across the world. The healthcare sector was severely impacted due to this outbreak, as the number of COVID-19 patients were increasing on a daily basis. 

Several clinical trials and research activities were halted during the pandemic, owing to the shortage of resources and strict lockdowns. The pandemic also hampered the growth of the global Malaria Vaccines Market, as many companies were focusing on developing COVID-19 vaccines. However, the market is estimated to witness growth in the post-pandemic era.

Key Takeaways:

The global Malaria Vaccines Market is expected to witness high growth, exhibiting a CAGR of 29.6 % over the forecast period, due to the growing adoption of growth strategies.

For instance, GlaxoSmithKline, PATH, Bharat Biotech and a nonprofit global health organization based in Seattle, U.S., declared signing a product transfer agreement in January 2021, for RTS,S/AS01E, a malaria vaccine. This agreement includes transferring of the grant of a license and manufacturing of the RTS,S antigen part of the vaccine.

North America is anticipated to witness significant growth in the global malaria vaccines for the market over the forecast period, owing to growing presence of key manufacturers and increasing research and development expenditure.

Major players operating in the global Malaria Vaccines Market are Taj Pharmaceuticals Limited, Actiza Pharmaceutical Private Limited, Amneal Pharmaceuticals LLC., AdvaCare Pharma, Hikma Pharmaceuticals PLC, Ipca Laboratories Ltd., Pfizer Inc., Hikma Pharmaceuticals PLC, Bliss GVS Pharma Ltd, GeoVax, AJANTA PHARMA, Sumaya Biotech, Sanofi, VLP Therapeutics, Taj Pharmaceuticals Limited, Strides Pharma Science Limited, Zydus Cadila, and Lupin.